Geron (GERN) Research & Development (2010 - 2026)
Geron's (GERN) quarterly Research & Development came in at $22.0 million in Q2 2026, up 1.35% year-over-year from $21.7 million in Q2 2025, and up 47.3% quarter-over-quarter from $15.0 million in Q1 2026.
Analysis
Geron (GERN) Research & Development (2010 - 2026) Analysis & Trends
Geron has disclosed Research & Development across 17 years of filings, most recently posting $22.0 million for Q2 2026.
- In Q2 2026, Research & Development rose 1.35% year-over-year to $22.0 million; the TTM figure through Jun 2026 stood at $71.6 million (down 10.94% YoY), while the FY2025 annual figure was $71.4 million, down 31.14% from the prior year.
- Research & Development came in at $22.0 million for Q2 2026 at Geron, up from $15.0 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $35.5 million in Q2 2023 to a low of $13.5 million in Q4 2025.
- Average Research & Development over 5 years is $24.0 million, with a median of $22.8 million recorded in 2022.
- Year-over-year, Research & Development surged 72.23% in 2023 and tumbled 48.67% in 2025.
- Over 5 years, Research & Development stood at $28.2 million in 2022, then increased by 16.66% to $32.9 million in 2023, then declined by 28.8% to $23.4 million in 2024, then tumbled by 42.18% to $13.5 million in 2025, then soared by 62.6% to $22.0 million in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $22.0 million in Q2 2026, $15.0 million in Q1 2026, and $13.5 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 1.87 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 1.76 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 993.80 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.63 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -486.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 651.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 529.60 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 202.02 Mn |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | 22.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 22.03 Mn |
| Mar 31, 2026 | 14.96 Mn |
| Dec 31, 2025 | 13.55 Mn |
| Sep 30, 2025 | 21.07 Mn |
| Jun 30, 2025 | 21.74 Mn |
| Mar 31, 2025 | 15.08 Mn |
| Dec 31, 2024 | 23.43 Mn |
| Sep 30, 2024 | 20.15 Mn |
| Jun 30, 2024 | 30.78 Mn |
| Mar 31, 2024 | 29.37 Mn |
| Dec 31, 2023 | 32.91 Mn |
| Sep 30, 2023 | 29.43 Mn |
| Jun 30, 2023 | 35.49 Mn |
| Mar 31, 2023 | 27.22 Mn |
| Dec 31, 2022 | 28.21 Mn |
| Sep 30, 2022 | 24.60 Mn |
| Jun 30, 2022 | 20.61 Mn |
| Mar 31, 2022 | 22.10 Mn |
| Dec 31, 2021 | 24.15 Mn |
| Sep 30, 2021 | 18.53 Mn |